In this article, we will explore the fascinating world of JNJ-18038683. From its origins to its influence today, this topic arouses great interest and curiosity in individuals of all ages. Through a detailed and exhaustive analysis, we will address the most relevant and significant aspects related to JNJ-18038683, providing the reader with a broad and enriching perspective. Likewise, we will examine its impact in various areas, from culture to science, including its relevance in contemporary society. Ultimately, this article seeks to shed light on JNJ-18038683 and its importance in today's world.
JNJ-18038683 is a potent and selective antagonist of the 5HT7serotoninreceptor discovered by Johnson & Johnson. It has nootropic and antidepressant effects in both animal and human studies and has progressed to Phase II trials as an adjunctive treatment for improving cognition and mood in stable bipolar disorder; it has been found to reduce REM sleep (the lightest stage of sleep, elevated in depression) in humans and block circadian rhythm phase-shift advances in mice.
It binds to the 5-HT6 serotonin receptor with 10x less affinity. At relevant doses, inhibition of 5-HT6 would be expected to render pro-cognitive and anti-dementia effects.
References
^Bonaventure P, Dugovic C, Kramer M, De Boer P, Singh J, Wilson S, et al. (August 2012). "Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder". The Journal of Pharmacology and Experimental Therapeutics. 342 (2): 429–440. doi:10.1124/jpet.112.193995. PMID22570363. S2CID10418102.